0001209191-22-018283.txt : 20220311
0001209191-22-018283.hdr.sgml : 20220311
20220311184428
ACCESSION NUMBER: 0001209191-22-018283
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220310
FILED AS OF DATE: 20220311
DATE AS OF CHANGE: 20220311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Papiernik Antoine
CENTRAL INDEX KEY: 0001768408
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38829
FILM NUMBER: 22734672
MAIL ADDRESS:
STREET 1: 5403 BETSY ROSS DRIVE
CITY: SANTA CLARA
STATE: CA
ZIP: 95054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Shockwave Medical, Inc.
CENTRAL INDEX KEY: 0001642545
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 270494101
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5403 BETSY ROSS DRIVE
CITY: SANTA CLARA
STATE: CA
ZIP: 95054
BUSINESS PHONE: (510) 279-4262
MAIL ADDRESS:
STREET 1: 5403 BETSY ROSS DRIVE
CITY: SANTA CLARA
STATE: CA
ZIP: 95054
FORMER COMPANY:
FORMER CONFORMED NAME: ShockWave Medical, Inc.
DATE OF NAME CHANGE: 20150515
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-10
0
0001642545
Shockwave Medical, Inc.
SWAV
0001768408
Papiernik Antoine
C/O SHOCKWAVE MEDICAL, INC.
5403 BETSY ROSS DRIVE
SANTA CLARA
CA
95054
1
0
0
0
Common Stock
2022-03-10
4
S
0
5494
161.61
D
116757
I
By Sofinnova Capital VII FCPR
Common Stock
2022-03-10
4
S
0
17907
162.51
D
98850
I
By Sofinnova Capital VII FCPR
Common Stock
2022-03-10
4
S
0
19424
163.53
D
79426
I
By Sofinnova Capital VII FCPR
Common Stock
2022-03-10
4
S
0
12729
164.43
D
66697
I
By Sofinnova Capital VII FCPR
Common Stock
2022-03-10
4
S
0
4446
165.40
D
62251
I
By Sofinnova Capital VII FCPR
Common Stock
3551
D
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $161.00 to $161.96. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Represents shares directly held by Sofinnova Capital VII FCPR. The reporting person is one of the managing partners of Sofinnova Partners SAS, a French corporation and the management company of Sofinnova Capital VII FCPR. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $162.00 to $162.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $163.00 to $163.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $164.03 to $164.94. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $165.25 to $165.40. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
/s/ Wade Estey, as attorney-in-fact for Antoine Papiernik
2022-03-11